SCHEMBL3779205

SCHEMBL3779205

COC(=O)COc1ccc(Cl)c2nc(C)c(Cc3ccc(F)cc3)c(OC(C)C)c12

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
MAPT P10636 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38
CNR2 P34972 1/20 0.36
KDM4E B2RXH2 2/20 0.36
KMT2A Q03164 2/20 0.36
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
JAK2 O60674 1/20 0.35
P2RX3 P56373 4/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
POLB P06746 1/20 0.34
TRPC5 Q9UL62 1/20 0.34
LMNA P02545 2/20 0.34
PLA2G2A P14555 2/20 0.34
CXCR1 P25024 1/20 0.34
CXCR2 P25025 1/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3771722 0.93 PTGDR2 (0.44) ALDH1A1MAPTPTGDR2CNR2KDM4E
SCHEMBL3776958 0.91 PTGDR2 (0.45) PTGDR2P2RX3TRPC5LMNAPLA2G2A
SCHEMBL3772144 0.86 PTGDR2 (0.43) ALDH1A1PTGDR2CNR2KDM4EKMT2A
SCHEMBL3779488 0.86 ALDH1A1 (0.38) ALDH1A1MAPTCNR2KDM4EKMT2A
SCHEMBL3778911 0.84 PTGDR2 (0.53) PTGDR2KDM4EPLA2G2A
SCHEMBL3776193 0.83 KDM4E (0.39) ALDH1A1PTGDR2KDM4EKMT2ASMN1; SMN2
SCHEMBL3780089 0.83 PTGDR2 (0.39) ALDH1A1PTGDR2KDM4EKMT2ASMN1; SMN2
SCHEMBL3777990 0.82 PTGDR2 (0.56) ALDH1A1MAPTPTGDR2CNR2KDM4E
SCHEMBL3785291 0.81 PTGDR2 (0.50) ALDH1A1PTGDR2KDM4EKMT2ASMN1; SMN2
SCHEMBL3772529 0.80 ALDH1A1 (0.38) ALDH1A1MAPTPTGDR2CNR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928457-B1 QUINOLINES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-12-12 EP disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
EP-1928457-A2 QUINOLINES AND THEIR THERAPEUTIC USE Argenta Discovery Limited (GB) 2008-06-11 EP disclosed
WO-2007036743-A2 QUINOLINES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156600-A1 Quinolines and Their Therapeutic Use NR3C1, NR3C2, NR1H3 ALDH1A1 4201/4885MAPT 4787/4885PTGDR2 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.